Sussex Research Laboratories Inc., leading GalNAc and carbohydrate targeting ligand specialist, is excited to announce sponsorship of the 8th Annual OPT Congress - Oligonucleotide & Precision Therapeutics!
For over 25 years, we have enabled application of complex carbohydrate systems, including GalNAc and glycopeptides, in drug discovery, drug delivery, drug targeting, glycoconjugate vaccine development, immunotherapy, therapeutic enhancement and diagnostic/bio-analytical assay development. Visit us at booth 16 from March 13-14, 2023 in Boston, Massachusetts, USA!
About Sussex Research Laboratories Inc.: Sussex Research Laboratories Inc. is a global leader in Carbohydrate Synthesis. We excel at translating complex carbohydrate chemistries into unique, leading-edge products that enable researchers to explore and exploit glycobiology in applications that promote human health. Our product portfolio and contract research & development services enable our clients and partners to apply discoveries in glycomics for drug development & discovery, drug delivery & targeting, vaccine development and monoclonal antibody development. Experience glyco-enhancement of your small molecule, protein, oligonucleotide or other macromolecule through Sussex Research Laboratories Inc.. We are the GalNAc, Glycan, Ligand, Glycopeptide and Glycoconjugate Specialists. For more information visit www.sussex-research.com.
SHARE THIS ARTICLE ON:
Get product updates and announcements from Sussex Research in your inbox at no charge.
Sussex Research Laboratories Inc. to Attend the 25th Annual San Diego Glycobiology Symposium (SDGS)
March 20, 2023
Sussex Research Laboratories Inc. Appoints Dr. Corwin Nycholat to Advisory Board
February 3, 2023
Sussex Research Laboratories Inc. to Exhibit at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics
May 4, 2022
Sussex Research Laboratories Inc. to Exhibit at The American Peptide Symposium 2022 - "Peptide Science at the Summit"
April 26, 2022
Sussex Research Laboratories Inc. / Queen’s University collaboration receives support to develop novel small molecule therapies for COVID-19
May 21, 2020